Drivers include market share gains, a product launch super-cycle, OPSB adoption, and portfolio expansions like OSSIO. Key risks are timing of capital equipment/7D sales, variable international distributor selling patterns, and disciplined cash expansion (particularly impacting scoliosis and Brazil sets).
OrthoPediatrics projects $265M-$269M 2026 revenue and reiterates ~$25M adjusted EBITDA as it targets 2026 free cash flow break-even (NASDAQ:KIDS)
